BERKELEY, Calif.--(BUSINESS WIRE)--Dynavax Technologies (Nasdaq:DVAX) today announced the appointment of J. Tyler Martin, M.D. as Chief Medical Officer. Dr. Martin will manage Dynavax’s clinical affairs, including the development of Dynavax’s three current clinical-stage product candidates and three preclinical candidates, which are expected to enter clinical development within the next year.
